Glaxo failed to warn of diabetes drug risk
|
The widow and son of a Texas man who was taking a GlaxoSmithKline Plc diabetes drug at the time of his fatal heart attack claims the drugmaker failed to warn about the drug’s risks, according to a lawsuit.
The claim involves rosiglitazone, which is sold under the brand names Avandia and Advandamet. Investors have been bracing for a flood of litigation against Glaxo after a widely publicized medical report suggested Avandia increases the risk of heart attack.
The lawsuit was filed Tuesday by relatives of Larry Alan Stanford in the U.S. District Court for the Eastern District of Texas.
“Glaxo knew or should have known that its rosiglitazone drug greatly increased plaintiffs’ risks of having a heart attack and/or other negative cardiovascular consequences or of causing sudden cardiac death,” the lawsuit said.
Print Version
Tell-a-Friend comments powered by Disqus